B. Parshall Biography and Net Worth

Director of Cytokinetics

B. Lynne Parshall, Esq., has served as a member of our Board of Directors since February 2013. Ms. Parshall currently serves on the Board of Directors of Ionis Pharmaceuticals, and is a Senior Strategic Advisor to the company. From 1991 until January 2018 she served as the Chief Operating Officer of Ionis. She has held various positions of increasing responsibilities at Ionis since 1991. Prior to joining Ionis, Ms. Parshall was a partner at the law firm of Cooley Godward LLP. From July 2005 to August 2009, Ms. Parshall also served as a member of the Board of Directors of Cardiodynamics International Corporation. Ms. Parshall has served as a member of the Board of Directors of Regulus Therapeutics Inc. since January 2009. She is a member of the Licensing Executives Society and a member of the American, California, and San Diego bar associations. Ms. Parshall holds a J.D. from Stanford Law School and a B.A. from Harvard University.

What is B. Lynne Parshall's net worth?: The estimated net worth of B. Lynne Parshall is at least $1.03 million as of August 12th, 2024. Ms. Parshall owns 20,600 shares of Cytokinetics stock worth more than $1,027,116 as of November 20th. This net worth estimate does not reflect any other investments that Ms. Parshall may own. Learn More about B. Lynne Parshall's net worth.
How do I contact B. Lynne Parshall?: The corporate mailing address for Ms. Parshall and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on B. Lynne Parshall's contact information.
Has B. Lynne Parshall been buying or selling shares of Cytokinetics?: B. Lynne Parshall has not been actively trading shares of Cytokinetics during the last ninety days. Most recently, B Lynne Parshall sold 5,000 shares of the business's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $55.20, for a transaction totalling $276,000.00. Following the completion of the sale, the director now directly owns 20,600 shares of the company's stock, valued at $1,137,120. Learn More on B. Lynne Parshall's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 43 times. They sold a total of 432,011 shares worth more than $27,490,574.11. The most recent insider tranaction occured on November, 18th when CEO Robert I Blum sold 5,000 shares worth more than $252,750.00. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 11/18/2024.

B. Lynne Parshall Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/12/2024	Sell	5,000	$55.20	$276,000.00	20,600
7/29/2024	Sell	5,000	$59.84	$299,200.00	20,600
7/15/2024	Sell	5,000	$55.82	$279,100.00	20,600
7/1/2024	Sell	5,000	$54.22	$271,100.00	20,600
6/17/2024	Sell	5,000	$52.55	$262,750.00	20,600
10/19/2021	Sell	10,332	$35.73	$369,162.36

B. Lynne Parshall Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $49.86

$49.65

$50.95

50 Day Range

MA: $53.86

$49.86

$58.62

2 Week Range

Now: $49.86

$30.68

$110.25

Volume

1,063,163 shs

Average Volume

2,057,156 shs

Market Capitalization

$5.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.